Cetuximab (Erbitux) may be an active addition to chemoradiation and chemotherapy for the treatment of locally advanced esophageal cancer, according to the final results of an open-label, single-arm multicenter phase II study conducted in France by the Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR).1
http://www.ascopost.com/articles/february-15-2011/french-study-supports-cetuximab-in-esophageal-cancer